Synthesis and anticonvulsant activity of new 2,3-benzodiazepines as AMPA receptor antagonists

Farmaco

Volumn 54, Issue 3, 1999, Pages 178-187

  De Sarro, Angela ^a   De Sarro, Giovambattista ^b   Gitto, Rosaria ^c   Grasso, Silvana ^c   Micale, Nicola ^c   Zappalà, Maria ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b Dipto Med Sperim Clin Univ C   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

7,8 Methylenedioxy 4H 2,3 benzodiazepin 4 ones; AMPA receptor antagonists; Anticonvulsant activity

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR ANTAGONIST; ANIRACETAM; BENZODIAZEPINE DERIVATIVE; FLUMAZENIL; PENTETRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AUDITORY STIMULATION; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; ELECTRIC SHOCK; EPILEPSY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NEWBORN; NONHUMAN; SEIZURE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICONVULSANTS; BENZODIAZEPINES; FEMALE; MALE; MICE; MICE, INBRED DBA; MOLECULAR STRUCTURE; RECEPTORS, AMPA;

EID: 0033620391     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(99)00022-1     Document Type: Article

References (47)

1. Hicks T.P. The role of glutamate and its receptors in synaptic transmission. Stone T.W. CNS Neurotransmitters and Neuromodulators: Glutamate. 1995;201-215 CRC Press, New York.
2. Conn P., Pin J.-P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37:1997;205.
3. P. Krogsgaard-Larsen, J.J. Hansen (Eds.), Excitatory Amino Acid Receptors: Design of Agonists and Antagonists, Ellis Horwood, Chichester, UK, 1992.
4. D.T. Monaghan, R.J. Wenthold (Eds.), The Ionotropic Glutamate Receptors, Humana Press, New Jersey, 1997.
5. Ikonomidou C., Turski L. Glutamate in neurodegenerative disorders. Stone T.W. CNS Neurotransmitters and Neuromodulators: Glutamate. 1995;253-266 CRC Press, New York.
6. Danysz W., Parsons C.G., Bresink I., Quack G. Glutamate in CNS disorders. Drug News Perspect. 8:1995;261-277.
7. Krogsgaard-Larsen P., Ebert B., Lund T.M., Bräuner-Osborne H., Slok K.A., Johansen T.N., Brehn L., Madsen U. Design of excitatory amino acid receptor agonists, partial agonists and antagonists: ibotenic acid as a key lead structure. Eur. J. Med. Chem. 31:1996;515-537.
8. B.S. Meldrum (Ed.), Excitatory Amino Acid Antagonists, Blackwell, London, 1991.
9. Rogawski M.A. The NMDA receptor, NMDA antagonists and epilepsy therapy. Drugs. 44:1992;279-292.
10. Koek W., Woods J.H., Winger G.D. MK-801, a proposed non-competitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 245:1988;969-974.
11. Herting P.L. Competitive NMDA antagonists: results from animal models and first results in human. J. Neurochem. (Suppl.). 61:1993;S283C.
12. Morris R.G.M., Anderson E., Lynch G.S., Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 319:1986;774-776.
13. Desos P., Lepagnol J.M., Morain P., Lestage P., Cordi A.A. Structure-activity relationships in a series of 2(1H)-quinolones bearing different function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties. J. Med. Chem. 39:1996;197-206.
14. Lin Z., Kadaba P.K. Molecular targets for the rational design of antiepileptic drugs and related neuroprotective agents. Med. Res. Rev. 17:1997;537-572.
15. Sheardown M.G., Nielsen E.O., Hansen A.J., Jacobsen P., Honore T. 2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline: a neuroprotectant for cerebral ischemia. Science. 247:1990;571-574.
16. Buchan A.M., Lesiuk H., Barnes K.A., Li H., Huang Z.G., Smith K.E., Xue D. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke (Suppl. I). 24:1993;148-152.
17. Ohmori J., Sakamoto S., Kubota H., Shimizu-Sasamata M., Okada M., Kawasaki S., Nikada K., Togami J., Furuya T., Murase K. 6-(1H-Imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor. J. Med. Chem. 37:1994;467-475.
18. Donevan S.D., Rogawski M.A. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, non-competitive antagonist of AMPA/kainate receptor responses. Neuron. 10:1993;51-59.
19. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14:1993;325-331.
20. Chapman A.G., Smith S.E., Meldrum B.S. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466 in mice. Epilepsy Res. 9:1991;92-96.
21. Smith S.E., Durmuller N., Meldrum B.S. The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur. J. Pharmacol. 201:1991;179-183.
22. Chapman A.G., Al-Zubaidy Z., Meldrum B.S. Aniracetam reverses the anticonvulsant action of NBQX and GYKI 52466 in DBA/ 2 mice. Eur. J. Pharmacol. 231:1993;301-303.
23. Donevan S.D., Yamaguchi S.I., Rogawski M.A. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity. J. Pharmac. Exp. Ther. 271:1994;25-29.
24. Smith S.E., Meldrum B.S. Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat. Stroke. 23:1992;861-864.
25. Arvin B., Lekieffre D., Graham J.L., Moncada C., Chapman A.G., Meldrum B.S. Effect of the non-NMDA receptor antagonist GYKI 52466 on the microdialyzate and tissue concentrations of amino acids following transient forebrain ischemia. J. Neurochem. 62:1994;1458-1467.
26. Tarnawa I., Farkas S., Berzsenyi P., Pataki A., Andrasi F. Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466. Eur. J. Pharmacol. 67:1989;193-199.
27. De Sarro G., Chimirri A, De Sarro A., Gitto R., Grasso S., Giusti P., Chapman A.G. GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice. Eur. J. Pharmacol. 294:1995;411-422.
28. Chimirri A., De Sarro G., De Sarro A., Gitto R., Grasso S., Quartarone S., Zappalà M., Giusti P., Libri V., Constanti A., Chapman A.G. 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: novel AMPA receptor antagonists. J. Med. Chem. 40:1997;1258-1269.
29. Chapman A.G., Croucher M.J., Meldrum B.S. Evaluation of anticonvulsant drugs in DBA/2 mice with sound-induced seizures. Arzneim. Forsch. 34:1984;1261-1264.
30. Engstrom F.L., Woodbury D.M. Seizure susceptibility in DBA/2 and C57 mice: the effects of various convulsants. Epilepsia. 29:1988;389-395.
31. Ito I., Tanabe S., Kohda A., Sugiyama H. Allosteric potentiation of quisqualate receptors by nootropic drug aniracetam. J. Physiol. (London). 424:1990;533-543.
32. De Sarro A., De Sarro G., Gitto R., Grasso S., Micale N., Quartarone S., Zappalà M. 7,8-Methylenedioxy-4H-2,3-benzodiazepin-4-ones as novel AMPA receptor antagonists. Bioorg. Med. Chem. Lett. 8:1998;971-976.
33. Schuda P.F., Cichowicz M.B., Heimann M.R. A facile method for the oxidative removal of benzyl ethers: the oxidation of benzyl ethers to benzoate by ruthenium tetraoxide. Tetrahedron Lett. 24:1983;3829-3830.
34. Chapman A.G., Meldrum B.S. Non-competitive N-methyl-D-aspartate antagonists protect against sound-induced seizures in DBA/2 mice. Eur. J. Pharmacol. 166:1989;201-211.
35. De Sarro G.B., De Sarro A. Anticonvulsant properties of non-competitive antagonists of NMDA receptor in genetically epilepsy prone rats. Comparison with CPPene. Neuropharmacology. 32:1993;51-58.
36. McEntee W.C., Crook T.H. Glutamate, its role in learning, memory, and the aging brain. Psychopharmacology. 111:1993;391-401.
37. Chiamulera C., Costa S., Reggiani A. Effect of NMDA- and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning. Psychopharmacology. 102:1990;551-552.
38. Bliss T.V.P., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 361:1993;31-39.
39. Paternain A.V., Morales M., Lerma J. Selective antagonism of AMPA receptors unmasks kainate receptor-mediate responses in hippocampal neurones. Neuron. 14:1995;185-189.
40. Daly J.W., Padgett W.L., Shamin M.T. Analogues of 1,3-dipropyl-8-phenylxanthines: enhancement of selectivity at A1-adenosine receptors by aryl substituents. J. Med. Chem. 29:1986;1520-1524.
41. Collins R.L. Audiogenic seizures. Purpura P., Penry J.K., Tower D., Woodbury D.M., Walter R. Experimental Models of Epilepsy. 1972;347-372 Raven Press, New York.
42. Swinyard E.A., Brown W.C., Goodman L.S. Comparative assays of antiepileptic in mice and rats. J. Pharmacol. Exp. Ther. 106:1952;319-330.
43. Swinyard E.A., Woodhead J.M. Experimental detection, quantification and evaluation of anticonvulsants. Woodbury D.M., Penry J.K., Pippenger C.E. Epileptic Drugs. 1982;111-126 Raven Press, New York.
44. De Sarro G.B., Ongini E., Bertorelli R., Aguglia U., De Sarro A. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur. J. Pharmacol. 262:1994;11-19.
45. Dunham N.W., Miya T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Ass. 46:1957;208-209.
46. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effects experiments. J. Pharmac. Exp. Ther. 96:1949;99-113.
47. G.I. McPherson, LIGAND (release 2.0), Elsevier Biosoft, Cambridge, 1987.